Middle East healthcare shifts to resilient supply chains, early diagnosis and greener labs

Healthcare systems across the Gulf Cooperation Council are shifting procurement and delivery priorities toward supply-chain resilience, sustainable procurement and earlier disease detection after the Covid-19 pandemic exposed vulnerabilities in medical supplies and diagnostics networks. Diagnostics firms and health ministries are aligning on longer-term value in purchases, more efficient laboratory operations and expanded access to simpler diagnostic tests, while policymakers emphasise early diagnosis, preventative care and lifecycle sustainability.

"In our line of work, the stakes are simply too high for supply chains to fluctuate, because a delay in a diagnostic result directly impacts a patient’s treatment timeline," said Guido Sander, General Manager at Roche Diagnostics Middle East.

Context and details

The pandemic revealed how fragile global medical supply chains can be, prompting governments and providers to treat diagnostics infrastructure as a strategic priority. Sander warned that "fragmented, unreliable testing networks are a massive vulnerability," and framed diagnostics as integral to national security and universal healthcare systems.

Across the GCC, procurement strategies are moving away from lowest‑cost, short‑term purchases toward models that prioritise lifecycle costs, energy efficiency and waste reduction. Sander argued that "sustainability… means operating with a long-term mindset; ensuring more people can benefit from innovation today without compromising the world they will live in tomorrow." That emphasis is translating into demand for lower‑footprint instruments, leaner chemistry and digital workflows, which he said "translates into real, measurable value for ministries, payers, and ultimately, the patients."

Policymakers in the region are reportedly converging on a set of long‑term goals despite differing resources and system maturity. Key priorities include advancing early diagnosis, strengthening preventative care, and embedding sustainability into procurement and operations. A major focus is on diseases that have historically been underdiagnosed—Alzheimer’s disease is highlighted as a pressing example, with "an estimated 75% of people… undiagnosed" and many patients experiencing multi‑year delays before confirmation.

• Supply resilience: Treating diagnostics supply chains as strategic infrastructure to avoid delays that impact treatment timelines.
• Sustainable procurement: Prioritising long‑term value, reduced waste, and lower energy use in lab equipment and consumables.
• Early diagnosis: Expanding access to simpler tests to catch chronic and neurodegenerative diseases earlier in their course.
• Digitalisation: Building a digital intelligence backbone to enable population health management and disease prevention at scale.

Outlook

New diagnostic approaches aim to simplify testing and expand accessibility—"by replacing costly PET scans or invasive procedures with a simple… blood draw, we are opening the door to diagnosis at the absolute 'dawn' of the disease," Sander said—potentially shortening the time to diagnosis for conditions like Alzheimer’s. Digitalisation and AI‑led systems are expected to underpin the next phase of transformation, moving health systems away from isolated laboratories toward integrated, data‑driven care models that support population health management.

However, Sander cautioned that these advances will only deliver their full value if they are accessible: "All this innovation only matters if it translates into equitable access," highlighting an ongoing policy challenge for regional health systems as they seek to balance resilience, sustainability and inclusivity in healthcare delivery.